Home > Alliance

Alliance

Enabling Better and Faster Treatment for Patients with Hematologic Malignancies (HM).

 

The HARMONY Alliance is a European Network of Excellence for Big Data in Hematology, consisting of Publi-Private Partners and Associated Members.

Our goal is unlocking valuable knowledge on blood cancers, Hematologic Malignancies (HMs). 


Blood cancers, or hematologic cancers (e.g. leukemia, lymphoma, and myeloma), affect the production and function of blood cells and account for about 40% of cancer cases in children and about one third of cancer deaths. As many blood cancers are rare, and healthcare practice varies across EU, a lack of data on relevant outcomes represents a challenge for clinicians, researchers, and other decision-makers like regulators and HTA bodies, resulting in limitations for patient access to the best healthcare. The HARMONY Alliance aims to use "Big Data and Big Data analytics" to deliver information that will help to improve the care of patients with these diseases.


HARMONY will gather together, integrate and analyze anonymous patient data from a number of high-quality sources. This will help the team to define clinical endpoints and outcomes for these diseases, which are recognized by all key stakeholders in the Healthcare -systems. Meanwhile, the insights generated by the Alliance will facilitate and improve decision-making along the value chain in order to ultimately give the right treatment to the right patient at the right time. More broadly, this IMI project will result in a pan-European network of stakeholders with expertise in these diseases.

Link to the HARMONY at the IMI - Innovative Medicines Initiative website.


The HARMONY Alliance was established in January 2017, and will last for a period of 5 years. We are determined to create and implement new treatment strategies based on big data technologies. Our final deliverable is a Big Data platform that will integrate and harmonize information on blood diseases in order that they can be better understood and more optimally treated. 


Our Reason for Being

 

Because there is a lack of definition and alignment on outcomes that are important for all stakeholders and patients to get access to the right treatment at the right time, the development, approval and access to promising new treatments are delayed or prevented.


We Bring Together

 

Patient and societal organizations, hematologists and clinicians, medicines authorities and regulatory institutions, health technology assessment organizations, payers, policy makers and funding organizations, the pharmaceutical industry, information and communications technology companies, and other relevant European and international alliances.


Our Approach

 

We:

  • Collect, share, and harmonize Big Data from high-quality multidisciplinary sources.

  • Assess and integrate a large amount of molecular data to better understand outcomes in specific hematological malignancies.

  • Generate evidence to encourage healthcare systems to pay particular attention to the value of healthcare and to improve outcomes.

  • Facilitate drug development pipelines and accelerate the “bench-to-bedside” process in drug development.


 

Our focus

 

We are striving to unlock valuable knowledge across the spectrum of hematologic malignancies (blood cancers), including: multiple myeloma (MM), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkins lymphoma (NHL), myelodysplastic syndromes (MDS), and pediatric hematologic malignancies.


At a glance

 

Click on this link to view our short slideshow presentation.

 


How we are funded 

 

HARMONY Alliance is funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. HARMONY has received funding from IMI 2 Joint Undertaking and is listed under grant agreement No. 116026. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.

Read more at: www.imi.europa.eu